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Occurrence of exercise-induced and 
spontaneous wide complex tachycardia during 
therapy with flecainide for complex ventricular 
arrhythmias: A probable proarrhythinic effect 
Flecainide acetate, a new antiarrhythmic agent, possesses favorable pharmacqkiqetic and 
hemodynamid propertles and demonstrates highly favorable antiarrhythinic activity in patients 
with ventricular airhythmias. However,. thi proarrhythmlc potential of flecainlde deserves further 
ivaluation. In f  (13%) of 55 consecutive patients treated wlth oral flecainide, 290 to 600 
m’g/day, f6r. complex ventricular arrhythmias (including sustained ventrlCular tachycardjd in 14), 
wi observed the appearance of new or more sustained exercise-Induced (five patlents) or 
spontaneoui (two patients) wide complex tachycardla. The mechanism of wide complex 
tachycardia appeared to be ventricular tachychrdia in all seven. In our series, episodes were 
seif:remittl~ or succestifully treated. In four patients, wide complex .taohycardia did not recur 
during excirclse testing during alternative antiarrhythmic therapy (three patIe+) or no 
antiarrhythmlc therapy (one patient). Theie tibservatlons raise the possibility of flsqalnlde-related 
proarrhythmia, rriariifested as an Increased propensity to exerelse ,(actlvity)-Induced WI& 
complex tao.hycardlq which &ai not reliably predicted by results of Holter recording6 oi 
progiammed electrical stlmulqtion. Patlents wlth complex ventricular arrhythmias beginning 
long-term treatment wlth oral flecainide should be ciz&dered for treadmill exercise t&sting 
together with ambulatory monitoring as part of the initial assessment of drug efficacy. (AM HEART 
J lg67;113:1071.) 
hiaria I. Anastasiou-Nana, M.D., Jeffrey L. Anderson, M.D., James R. Stewart, M.D., 
Barry J. Crevey, M.D., Frank G. Yanowitz, M.D., Joan R. Ltitz, R.N;, and 
Theresa A. Johnson, R.N. &lt Lake City, Utah and Ann Arbor, Mich. 
Management of complex ventricular arrhythmias 
remains a therapeutic prqblem in many in&&es 
because the efficacy of antiarrhythmic agents may 
be inadeqbate oi adverse effects intolerable.1-4 Ai 
Adverse effect t&t is being increasingly recognized 
in antiarrhythmic therapy is .the occurrence of 
arrhythmogenic activity. Such “proarrhythmic” 
effects may include increases in ectopic be& fre- 
quency or, of &ore concern, new or more frequent or 
longer episodes of sustained ventricular tachycardia 
(VT), torsade de pointes tachycardia, or ventricular 
fibrillation and sudden death.5 
Flecainide acetate, on6 of the newest of approved 
. 
antmrrhythmic agents, hti been shown to possess 
favorable pharmacokirietic properties in clinical 
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studies6 (complete absorption after oral administra- 
tion, no fist-pass effect, no sigriificant metabolites, 
and plasma elimbation haIf-lifci of 20 hours), and t+ 
possess a high therapeutic ratio in suppressing vbn- 
tricular arrhythmias.‘.l3 its common noncardiac 
adverse eff&a include blurred vision, liihtheadqd- 
ness; and dizziness, which resolve with time or with 
reduction to smaller but often still effective doses.14 
Cardiac adverse eff&$s (provocation of con&&on 
disturb&%, heart failure, and proarihythmia) 
remain a m&jor area requiring additional observa- 
tions. cinly a few reports exist about the possible 
prtirhythmic effecti of flecainide.*5-*s We report 
herein our obsetiatio& of wide complex tachycardia 
occtiring either spo&aneously or during exercise 
testing hi a consecutive series of patients treated 
with flecainide for complex ventricular arrhythmias 
in our institutionti. 
METHOD& 
Pitient chara&eristics. Over a 6l-month period, fle- 
cainide was administered to a total of 55 patients, 38 men 
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Table I. Selected patient characteristics 
Treatment 
Clinical Baseline Holter Flecainide * Duration of 
Patient Age Cardiac arrhythmia Baseline Holter TPVCslRPVCslhr dose treatment at 
No. Sex (yr) diagnosis diagnosis EF TPVCslRPVCslhr % A us baseline (mglday) time of event (mo) 
1 M 71 CAD PVC;, VCs, 0.39t 123/0.21 170fNA 200 0.9 
VT,, f38%/~~t 
2 M 68 CAD PVCs, VCs, 0.59t 28115.7 910.7 300 2.9 
VTiS 197%/188% 
3 M 55 CAD AF, PVCs, VCs, 0.19s EPS-V flutter, EPS-VT not 400(1 0.3 
VT,,, VT/VP (15 beats) induced 
4 F 63 VHD PVCs, VCs, o.ssg 147112 2810.45 400 28 
VTNS iSl%/i96% 
5 M 60 CAD PVCs, VCs, 0.475 156/6.3 0.0910 f300/1 1.9 
VTNS 
6 M 69 VHD PVCs, VCs, 0.558 1015/94.3 
1100%/l100% 4oo 
1.510.25 21.4 
VTNS, VT, 1100%/mO% 
7 F 43 VHD PVCs, VCs, 0.598 1939/o 0.13/o 500(1 3.1 
VTNs, ?VT,** iloo%,/- 
Totals 5 M 61+ 10 CAD=4 0.49 * 400+129 Median = 2.9 
2F yr VHD=3 0.16 Range = 0.3-28 
Abbreviations: AF = atria1 fibrillation; CAD = coronary artery disease; EF = ejection fraction; EPS = electropbysiologic study; PVCs = premature 
ventricular complexes; RPVCs = repetitive PVCs; TPVCs = total PVCs; VCs = ventricular couplets; VT,, = nonsustained ventricular tacbycardia; 
VHD = valvular heart disease; VTNF = ventricular tacbycardiahentricular fibrillation; VT, = sustained ventricular tacbycardia; NA = not available. 
*At time of event. 
tcontrast derived. 
$Repetitive beats not available; however, 24-hour Halter on Recainide 1 month previously showed 88 A suppression of total PVC&. 
§Ecbo derived. 
[Pose begun or adjusted upward within 6 days. 
TRadionuclide derived. 
**History of “tacbyarrbytbmia” but no documented VT on baseline Holters (~2) or exercise test. 
and 17 women (average age 59.7 years; range 32 to 79 
years). Patients were treated with the drug for a median of 
6 months (range 0.07 to 61 months). Fourteen patients 
(25%) had a history of sustained ventricular tachyar- 
rhythmia. Sixteen received oral flecainide after electro- 
physiologic study with programmed electrical stimulation 
for induction of VT. Thirty-nine were given oral flecainide 
guided by noninvasive methods, without electrophysiolog- 
ic evaluation. Ventricular arrhythmias were associated 
with coronary artery disease in 29 patients, valvular heart 
disease in eight, dilated cardiomyopathy in three, primary 
rhythm disorder (without other evident heart disease) in 
13, hypertension in one, and sick sinus syndrome (with a 
pacemaker) in one. 
Study design. Records of all patients treated with 
flecainide were reviewed retrospectively for the occur- 
rence of documented new or unexpected wide complex 
tachycardias. Tachycardias which were more frequent, 
more sustained, and/or less well tolerated were also in- 
cluded. The mechanism and morphology of tachycardia 
was confirmed by careful review of rhythm strips during 
tachycardia by one of us otherwise unfamiliar with the 
patient history (F.Y.). Fatients in the electrophyaiologic 
study group (n = 16) were subjected to continuous in- 
hospital monitoring and repeat programmed electrical 
stimulation to determine initial drug efficacy. Other 
patients underwent serial noninvasive monitoring. Clini- 
cal assessments were made initially monthly (for 2 to 3 
months), then every 3 months, and ambulatory 24-hour 
monitor recordings were performed during initial and 
subsequent dose adjustments and at least every 6 months 
thereafter. Exercise testing was performed initially during 
therapy and repeated as clinically indicated during follow- 
up. Sustained VT was defined as that lasting for 215 
seconds.1g 
Drug administration. Flecainide dosage ranged from 
200 to 600 mg/day (median 200 mg/day initially, 300 
mg/day at latest follow-up). Flecainide was given in two or 
(occasionally) three divided doses. Plasma concentration 
of flecainide was measured by gas-liquid chromatogra- 
ph.7 
RESULTS 
Of the 55 patients who were treated with oral 
flecainide, seven (13 % 70) developed sustained (~15 
seconds) wide QRS complex tachycardia spontane- 
ously (n = 2) or during exercke testing (n = 5). 
Relevant clinic&l information for these seven 
patients is presented in Table I. &try characteris- 
tics did not readily distinguish this small group of 
patients from the other 48: four of seven had 
coronary artery disease, and three had experiericed 
episodes of sustained VT or ventricular fibrillation; 
ejection fraction averaged 0.49 with a wide range 
(0.19 to 0.68). All seven patients had complex ven- 
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Fig. 1. Representative ECG strips from patient No. 1 at baseline and during wide complex tachycardia 
(WCT). 
Fig. 2. Representative ECG strips from patient No. 2 at baseline and during wide complex &hyc&ia, 
(WCT). 
Fig. 3. Representative ECG strips from patient No. 3. 
tricular arrhythmias including couplets and VT 
salvos (23 beats) at baseline. Representative ECG 
recordings before and during wide complex tachy- 
cardia are presented in Figs. 1 to 4. The tachycardia 
mechanism on careful review was thought to repre- 
sent VT in all seven. Duration of tachycardia ranged 
from 15 seconds to 2 days (Table II). Tachycardia 
caused syncope in two, lightheadedness in two, and 
he& palpitations and chest discomfort in one each; 
it was asymptomatic in one. In our series, no patient 
died as a result of wide complex tachycardia. Tachy- 
cardia refractory to cardioversion was not encoun- 
tered. Conversion was spontaneous in six and 
required overdriving with a pacemaker in one. 
With respect to the possibility of ischemia- 
induced VT, no patient developed chest pain prior 
to the arrhythmia induction; in two, the exercise test 
was read as suggestive of myocardial ischemia. Fle- 
cainide was discontinued in all patients. Subsequent 
exercise treadmill testing was performed in four 
patients during alternative antiarrhythmic therapy 
(one each on tocainide [patient No. 23, procainamide 
[patient No. 31, and amiodarone [patient No. 71 or 
no antiarrhythmic therapy [patient No. 11) and did 
not reinduce VT. 
Median flecainide acetate plasma concentration 
was 0.89 &ml (range 0.6 to >1.3) in the five 
patients in whom blood levels were available near to 
or at the time of the arrhythmia. Concurrent thera- 
py included low-dose beta blockers in only two 
patients (Nos. 2 and 7). Arrhythmia during flecain- 
ide occurred in the absence of a clinical history of 
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Abbreviations: ETT = exercise treadmill test; LBBB = left bundle branch block; NA = not available (not measured at time of event); RBBB = right bundle 
branch block; WCT, = sustained wide complex tachycardia. 
*Termination of VT was spontaneous in all except patient No. 6, who was converted with ventricular overdrive pacing. In patient No. 4, termination 
followed discontinuation of flecainide. 
tTime from event, 1 day to 9.6 months (no change in Aecainide dose over this period). 
IMechanism proved to be VT by demonstration of AV dissociation on an intraatrial recording. 
@Transient VT (60 set) had occurred once previously and during therapy with procainamide after exercise. 
$Exercise VT also induced on a second occasion lasting 1% minutes and finally spontaneous VT lasting 3 hours noted on another occasion, converting after 
lidocaine therapy (flecainide then stopped). 
previous sustained tachycardia in four patients 
(Nos. 1, 24, and 5). In one patient (No. 3), cardiac 
arrest (ventricular fibrillation), probably related to 
ischemia, had occurred, but monomorphic sustained 
VT had not been subsequently documented. A 
summary of three representative cases is presented 
below. 
Case 1. A 71-year-old man with a long-standing 
history of hypertension developed frequent complex 
premature ventricular complexes after an anterior 
wall myocardial infarction. Salvos but no sustained 
VT were noted on baseline monitoring. Flecainide, 
200 mg/day, was prescribed. After treatment for 1 
year, temporary discontinuation of the drug allowed 
documentation of drug effect (88% ectopic suppres- 
sion). Because of complaints of left precordial dis- 
comfort, he underwent thallium exercise testing on a 
treadmill 1 month later. Of note, Holter recording 
near the time of exercise testing showed loss of 
arrhythmia control (Table I). Baseline ECG showed 
left bundle branch block (QRS = 170 msec). After 
exercise for 2% minutes into stage I of a standard 
Bruce protocol, he began to look gray and started to 
stagger. Blood pressure became imperceptible, and 
he lost consciousness. His ECG rhythm strip at that 
time showed a very wide complex tachycardia 
(QRS = 260 msec, rate 125 bpm) (Fig. 1). Clinical 
and rhythm recovery occurred spontaneously within 
1 to 2 minutes after he was laid down in bed. 
(Thallium imaging was suggestive of a lateral wall 
defect; coronary angiography showed stenosis of a 
diagonal branch.) Repeat exercise tasting on no 
antiarrhythmic therapy was performed 3 weeks lat- 
er. Exercise treadmill testing was limited by chest 
pain; however, wide complex tachycardia did not 
OCCW. 
Case 2. A 68-year-old man had a long-standing 
history of coronary artery disease manifested by a 
myocardial infarction 20 years ago. Coronary bypass 
graft surgery was performed 2 years previously 
because of worsening angina. His course was also 
complicated by complex (but unsustained) ventricu- 
lar arrhythmias unresponsive to four conventional 
antiarrhythmic drugs (quinidine, procainamide, 
lidocaine, and &blockers). Flecainide, 150 mg twice 
a day, was initiated with 90% suppression of 
ventricular ectopy. He subsequently underwent rou- 
tine exercise treadmill testing. After exercising for 
5% minutes on a standard Bruce protocol, he sud- 
denly developed wide complex tachycardia, rate 150 
bpm, accompanied by lightheadedness (Fig. 2). 
Exercise was stopped and sinus rhythm was restored 
spontaneously after 15 seconds. Plasma flecainide 
level was 0.60 @/ml. Flecainide was discontinued 
and tocainide started. On repeat exercise treadmill 
teating 7 day8 later, VT did not occur. 
Case 3. A 55year-old man had coronary artery 
disease manifested by two myocardial infarctions. 
He had also undergone five-graft coronary artery 
bypass surgery. He subsequently experienced cardi- 
ac arrest after which he was treated ,with procain- 
amide for complex ventricular arrhythmias on 
ambulatory monitoring, with only partial suppres- 
sion but without recurrence of arrest. Baseline elec- 
trophysiologic testing induced nonsustuined poly- 
morphic VT. Oral flecainide, 200 mg twice a day, 
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Duration* Morphology 
of WCT of WCT 
Closestt flecainide 
level (nglml) 
60 set Undetermined 
15 set Polymorphous 
>15 set RBBB 
l-2 days LBBB 
530 set Undetermined 
>1 hrt, @ LBBB 
2 minf LBBB 








0.91 + 0.26 
was prescribed. On the fourth day of therapy, he 
experienced a syncopal episode during a hot shower. 
On repeat electrophysiologic study, no VT was 
induced. Because of continued suspicion of sponta- 
E 
5 
neous VT, he underwent bicycle ergometry, which r, 
induced wide complex tachycardia, rate 167 bpm, g 
with loss of consciousness (Fig. 3). Spontaneous E 
conversion to his usual rhythm (atrial fibrillation) v3 
mide), wide complex tachycardia was not induced. 
DISCUSSION 
The distinction between arrhythmogenic effects 
and therapeutic failure of antiarrhythmic drugs is 
difficult. Thus, we evaluated a consecutive series of 
55 patients treated with flecainide by one group of 
investigators and reported on all occurrences of 
paroxysmal wide complex tachycardia that were 
unexpected or more frequent. We observed seven 
instances (13% incidence). Of interest, in five of 
these, tachycardia induction occurred during exer- 
cise testing. This observation suggests the possibili- 
ty of a sympathoadrenal, ischemic, and/or other 
exercise or rate-related factor in arrhythmia occur- 
rence. 
Explanations for wide complex tachycardia occur- 
rence other than flecainide induction should also be 
considered. Flecainide substantially slows cardiac 
conduction as part of its therapeutic effects, causing 
increases in QRS intervals which may average 20% 
to 25 % at therapeutic blood levels and which may be 
as great as 30% to 50% in some patients.‘O* ls The 
possibility that wide complex tachycardia during 
exercise might represent a rate-related increase in 
intraventricular conduction delay must therefore be 
strongly considered. However, more bizarre QRS 
changes were observed during tachycardia than 
Fig. 4. Representative ECG strips from patient No. 6. 
would be expected from classic rate-related bundle 
branch block alone, Atrioventricular dissociation 
was frequently suggested (and proved with an 
intraatrial wire in patient No. 6), and hemodynamic 
deterioration (presyncope or syncope, hypotension) 
was often noted. On careful review of rhythm strips 
during wide complex tachycardia, the mechanism 
appeared to be VT in all seven. Four of our patients 
had ischemic heart disease; exercise-induced ische- 
mia might also lead to bundle branch block as a 
manifestation. However, either wide complex tachy- 
cardia occurred in the absence of chest pain or 
preceding ST segment depression or repeat exercise 
testing on alternative therapy failed to reproduce 
wide complex tachycardia. Only in patients Nos. I 
and 2 was an ischemic response noted and might be 
considered as a cofactor. 
Clues to risks of clinical proarrhythmias may be 
provided by animal models. In a canine postinfarc- 
tion model of sustained VT, Zimmerman et alzo 
found high-dose flecainide (3 to 10 mg/kg intrave- 
nously) to be arrhythmogenic. In a series of 15 dogs, 
flecainide infusions caused arrhythmias in five, con- 
sisting of spontaneous VT in four (after 10 mg/kg 
drug) and new electrophysiologic induction of VT in 
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one (nonsustained VT converted to sustained VT). 
VT was resistant to cardioversion in three animals. 
Proarrhythmia was dependent on drug concentra- 
tion with adverse rhythms occurring in five of five 
with plasma levels >3 pg/ml vs one of ten with lower 
levels. Proarrhythmia also correlated with ventricu- 
lar dysfunction, occurring in four of six with large vs 
one of eight with small infarctions. Much lower 
flecainide doses and associated plasma levels pertain 
in clinical practice, however. 
During clinical investigational administration of 
flecainide, an overall incidence of proarrhythmia, as 
judged by the individual investigating physician, has 
averaged 7 % , of which three fourths have taken the 
form of sustained tachyarrhythmia (primarily ven- 
tricular), an incidence of 5%.15*21 However, the risk 
of proarrhythmia has not been uniform across 
patient subgroups. Substantial increments in risk 
have been noted in the presence of significant 
organic heart disease (ventricular dysfunction) and 
more malignant baseline arrhythmias (nonsustained 
and especially sustained VT).21 Any proarrhythmic 
event was reported in 1.7% of patients treated for 
symptomatic premature ventricular complexes only 
vs 16.4% in those with prior sustained VT events. 
Moreover, proarrhythmia risk was twice as great in 
those with structural heart disease as in those 
without it (7.4% vs 3.6%). Clinical proarrhythmia 
also appears to be dose related especially in patients 
with underlying sustained VT: the incidence of a 
significant proarrhythmic event was 26% in a high- 
initial-dose (400 mg/day) compassionate use trial vs 
13% in a low-initial-dose (200 mg/day) study.21 In 
our study, patients Nos. 5 and 7 appear to fulfill the 
risk criteria of high dosage (>406 mg/day) and high 
plasma drug levels (1.0 and >1.3 pg/ml). Patient No. 
3 was at high risk because of a history of cardiac 
arrest and markedly depressed ventricular function. 
Patients Nos. 1, 2, and 4 were perceived to be at 
intermediate or lower risk of an adverse rhythm 
event, given the previous history of nonsustained 
VT with or without ventricular dysfunction. 
The distinction between drug failure and proar- 
rhythmia is often difficult to make. However, con- 
cern can be raised about the possibility of underes- 
timating the incidence of proarrhythmia in large 
data base reviews because of investigator bias or 
initial inexperience with unexpected types of proarr- 
hythmic events. Thus, in our series, all patients with 
documented wide complex tachycardia from a single 
investigator group series, excluding patients who 
initially failed therapy, are described. Our approach, 
if anything, might overestimate the role of flecainide 
by including all suspicious tachycardias. Our obser- 
vations about proarrhythmia risk, however, are con- 
sistent with previous laboratory and clinical obser- 
vations and also emphasize the potential for the 
combination of flecainide therapy and exercise to 
convert nonsustained to sustained VT. Previous 
sustained, monomorphic VT had occurred in one or 
possibly two patients; in both of these patients (Nos. 
6 and 7), VT during increasing doses of flecainide 
became more frequent and more sustained (e.g., 
patient No. 6, lasting >l hour; patient No. 7, 
induced on multiple treadmill tests and occurring 
spontaneously, lasting up to 3 hours, despite reduc- 
tion in isolated ectopic events). 
No directly comparable studies of the proarrhyth- 
mic effects of various other antiarrhythmic drugs in 
the same patient population have been reported. 
However, the overall reported incidence of 7% with 
flecainide15,21 compares favorably with the range of 
5% to 15% reported for various other agents in the 
experience of one large arrhythmia treatment cen- 
ter.5 Of concern, however, is the form of proarrhyth- 
mia observed with class IC agents, that is, sustained 
VT.21 Cases of difficult to resuscitate VT, including 
fatal cases, have also been observed rarely with 
flecainide.15sz1 We did not observe this form in our 
series of patients. Our patient population as a whole 
may be considered to be at intermediate rather than 
higher risk of proarrhythmia, as defined by the 
severity of presenting clinical arrhythmias and ven- 
tricular dysfunction .‘l Although the wide complex 
tachyarrhythmias observed in our group were not of 
the lethal variety (incessant or conversion resistant), 
which has occasionally been observed in very high- 
risk patient groups, they were nonetheless regarded 
as serious and unexpected and may be of the type 
more frequently observed in clinical practice. 
The observation in our series that wide complex 
tachycardia was frequently induced by treadmill or 
ergometric testing, even in the face of suppression of 
ambient ventricular ectopy (patients Nos. 2 and 4 to 
7) or electrophysiologically noninducible VT (pa- 
tient No. 3), has suggested to us an exercise-related 
mechanism. In this regard, it would be of interest to 
test the hypothesis that concurrent beta blocker 
therapy might influence the risk of exercise-stimu- 
lated wide complex tachycardia (VT) by limiting the 
heart rate and sympathetic response to exercise. 
Hirsowitz et al.22 evaluated the role of beta-blocking 
agents as adjunct therapy to membrane-stabilizing 
drugs (including some class IC agents) in malignant 
ventricular arrhythmias by means of ambulatory 
monitoring and exercise testing.22 The major contri- 
bution of beta blocker therapy was the reduction of 
the incidence of runs of VT during exercise testing 




patient8 Were on 
of exercise tests). In our study, two 
beta blockers (Nos. 2 and 7), and 
five +vere not. Flecainide haa been combined with 
beta blockers in therapy of postmyoca~M infarct 
arrhythmias in the Cardiac Arrhythmia Pilot Study 
(CAPS)29 with a low incidence (3%,) of proarrhyth- 
mic events. 
In conclusion, wide complex tachycardia with 
features of m occurred as the principal adverse 
rhythm manifestation during fleeainide therapy of 
patients with complex ventricular arrhythmias and 
occurred independently of the response of isolated 
ectopic beats during ambulatory iedording. Our 
observations, coupled with other reports, are consis- 
tent with an increased propensity for proarrhythmia 
in those with structural heart disease (especially 
coronary artery disease with left ventricular dys- 
function) and with more malignant underlying 
arrhythmias (nonsustained and sustained VT). Our 
experience suggests exercise testing to be a poten- 
tially arrhythmogenic stimulus in several patients. 
Other factors (rate-related conduction delay, exer- 
cise ischemia) might be considered as cofactors in 
individual patients. This leads to the proposal that 
routine exercise. testing be used to &valuate the 
propensity for activity-related proarrbythmia risk in 
patients treated with flecainide, especially in those 
at high risk (i.e., preexistent nonsustained or sus: 
tained VT and/or ventricular dysfunction). Future 
trials should use a prospective design with routine 
pre- and post-therapy exercise testing. These trials 
might also test the interaction of beta blockers in the 
exercise induction of arrhythmias during flecainide. 
Improved prediction and detection of the proarr- 
hythmic potential of flecainide is important for the 
safe and effective use of this important new agent. 
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